Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-P+Cb+PD1 Inhibitor Neoadjuvant Therapy for Early TNBC
NCT06817525Phase 2Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Nov 2024
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of paclitaxel in triple-negative breast cancer (TNBC) (2 arms), sponsored by Henan Cancer Hospital. Primary endpoint: Pathological Complete Response rate. Started Nov 2024; status: recruiting.
02
Drugs
paclitaxel
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06817525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06817525.